Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SANA 
Sana Biotechnology Inc (SANA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: SANA (3-star) is a STRONG-BUY. BUY since 20 days. Simulated Profits (23.74%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.14
1 Year Target Price $8.14
| 4 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 179.05% | Avg. Invested days 27 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.26B USD | Price to earnings Ratio - | 1Y Target Price 8.14 |
Price to earnings Ratio - | 1Y Target Price 8.14 | ||
Volume (30-day avg) 8 | Beta 1.91 | 52 Weeks Range 1.26 - 6.55 | Updated Date 10/31/2025 |
52 Weeks Range 1.26 - 6.55 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.1882 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.3% | Return on Equity (TTM) -109.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1034102425 | Price to Sales(TTM) - |
Enterprise Value 1034102425 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.08 | Shares Outstanding 257250485 | Shares Floating 156693080 |
Shares Outstanding 257250485 | Shares Floating 156693080 | ||
Percent Insiders 7.52 | Percent Institutions 77.99 |
Upturn AI SWOT
Sana Biotechnology Inc
Company Overview
History and Background
Sana Biotechnology Inc. was founded in 2018. It focuses on developing engineered cells as medicines for various diseases. The company has rapidly grown through significant fundraising and strategic acquisitions, aiming to revolutionize cell and gene therapy.
Core Business Areas
- In Vivo Delivery: Developing technologies to deliver genes directly into cells within the body, targeting specific tissues or organs.
- Ex Vivo Cell Engineering: Engineering cells outside the body to enhance their therapeutic properties before transplanting them back into the patient.
- Hypoimmune Technology: Creating cells that are invisible to the immune system, allowing for broader use and reduced rejection risk.
Leadership and Structure
Steve Harr, MD, is the CEO. The company has a board of directors and operates with distinct research and development teams focused on different therapeutic areas and technology platforms.
Top Products and Market Share
Key Offerings
- SGK-001 (ALLO-CAR19): An allogeneic CAR T-cell therapy targeting CD19 for B-cell malignancies. Currently in early-stage clinical trials. Market share is currently negligible due to its early stage of development. Competitors include Kite Pharma (GILD), Novartis (NVS), and Bristol Myers Squibb (BMY) in the CAR-T space. These competitors have approved CAR-T therapies with significant market share in relapsed or refractory large B-cell lymphoma.
- SC291 (Hypoimmune Cells): A pre-clinical program utilizing Sana's hypoimmune technology to create cells that evade immune detection, potentially applicable to various therapeutic areas including Type 1 Diabetes. Market share is zero (preclinical). Competitors are companies working on islet cell transplantation and immune tolerance strategies.
Market Dynamics
Industry Overview
The cell and gene therapy industry is experiencing rapid growth driven by technological advancements and increasing clinical success. High unmet medical needs and significant investment drive innovation.
Positioning
Sana Biotechnology aims to be a leader in cell and gene therapy by developing novel delivery technologies and creating hypoimmune cells. Their competitive advantage lies in their unique technology platform aimed at addressing limitations of existing cell and gene therapies.
Total Addressable Market (TAM)
The TAM for cell and gene therapy is projected to reach hundreds of billions of dollars by 2030. Sana is positioned to capture a significant share of this market through its broad pipeline and innovative technologies.
Upturn SWOT Analysis
Strengths
- Novel technology platform (hypoimmune cells)
- Strong leadership team
- Significant funding and resources
- Broad pipeline of preclinical and clinical programs
Weaknesses
- Early stage of clinical development
- High cash burn rate
- Dependence on technology platform validation
- Regulatory hurdles in cell and gene therapy
Opportunities
- Expanding therapeutic applications of cell and gene therapy
- Partnering with established pharmaceutical companies
- Securing regulatory approvals for key products
- Advancing delivery technologies to improve efficacy
Threats
- Competition from established players in cell and gene therapy
- Clinical trial failures
- Regulatory challenges and delays
- High manufacturing costs
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- CRISPR Therapeutics (CRSP)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
Competitive Landscape
Sana's advantage lies in its novel hypoimmune technology. However, it faces competition from established players with approved products and extensive resources.
Major Acquisitions
Gordian Bio
- Year: 2024
- Acquisition Price (USD millions): 150
- Strategic Rationale: Adding the senolytic medicines field and team to Sana's pipeline.
Growth Trajectory and Initiatives
Historical Growth: Sana's growth has been driven by its technological advancements and clinical trial progress. Its valuation has been influenced by investor sentiment towards the cell and gene therapy space.
Future Projections: Future growth depends on clinical trial successes, regulatory approvals, and successful commercialization of its products. Analyst estimates vary widely due to the uncertainty inherent in biotechnology development.
Recent Initiatives: Recent initiatives include advancing key clinical trials, expanding its technology platform, and seeking strategic partnerships.
Summary
Sana Biotechnology is an innovative cell and gene therapy company with a promising technology platform. The company has strong financial backing and a capable leadership team. However, it faces significant risks associated with clinical development and competition from established players. Sana's success depends on validating its technology platform and achieving regulatory approvals.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Sana Biotechnology Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and past performance is not indicative of future results. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sana Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-02-04 | President, CEO & Director Dr. Steven D. Harr M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 194 | Website https://www.sana.com |
Full time employees 194 | Website https://www.sana.com | ||
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.